Can the medicine for treatment of rare disorder spinal muscular atrophy (SMA) be made available at lower price in India if it is supplied to the neighbouring countries Pakistan and China at a cheaper rate, the Supreme Court has sought to know from the manufacturer of the drug, Risdiplam.